Skip to content
Triptorelin
Trelstar, Triptodur (triptorelin) is a protein pharmaceutical. Triptorelin was first approved as Trelstar on 2000-06-15. It is used to treat prostatic neoplasms in the USA. It is known to target gonadotropin-releasing hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
Trade Name
FDA
EMA
Trelstar, Triptodur
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triptorelin pamoate
Tradename
Company
Number
Date
Products
TRIPTODUR KITAzurityN-208956 RX2017-06-29
1 products, RLD, RS
TRELSTARVerity PharmaceuticalsN-020715 RX2000-06-15
1 products, RLD, RS
TRELSTARVerity PharmaceuticalsN-021288 RX2001-06-29
1 products, RLD, RS
TRELSTARVerity PharmaceuticalsN-022437 RX2010-03-10
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
trelstarNew Drug Application2020-10-01
triptodurNew Drug Application2019-04-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
prostatic neoplasms—D011471C61
Agency Specific
FDA
EMA
Expiration
Code
TRIPTORELIN PAMOATE, TRIPTODUR KIT, AZURITY
2024-06-29ODE-149
Patent Expiration
Patent
Expires
Flag
FDA Information
Triptorelin Pamoate, Trelstar, Verity
101661812029-06-30DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L02: Endocrine therapy antineoplastic and immunomodulating agents
— L02A: Hormones and related agents
— L02AE: Gonadotropin releasing hormone analogues, endocrine therapy drugs
— L02AE04: Triptorelin
HCPCS
Code
Description
J3315
Injection, triptorelin pamoate, 3.75 mg
J3316
Injection, triptorelin, extended-release, 3.75 mg
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRIPTORELIN
INNtriptorelin
Description
Triptorelin is an oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-tryptophyl, leucyl, arginyl, prolyl and glycinamide residues joined in sequence. It is an agonist analogue of gonadotropin-releasing hormone. It has a role as a gonadotropin releasing hormone agonist, an antineoplastic agent and a contraceptive drug.
Classification
Peptide
Drug classprehormones or hormone-release stimulating peptides
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Identifiers
PDB—
CAS-ID57773-63-4
RxCUI38782
ChEMBL IDCHEMBL1201334
ChEBI ID63633
PubChem CID25074470
DrugBankDB06825
UNII ID9081Y98W2V (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
2798
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Q92644
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,887 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
387 adverse events reported
View more details